Lilly buys Europe-rooted AtaiBeckley for up to $3.8B

Why it matters: The deal is a major validation for Europe’s psychedelic drug development ecosystem and for German investor Christian Angermayer, who helped launch atai Life Sciences in Berlin as an umbrella for experimental mental health companies.

• Lilly will pay $2.8 billion (€2.45 billion) in cash at closing, with shareholders eligible for up to another $1 billion (€0.9 billion) if two DMT-based programmes reach specified clinical and regulatory milestones. The acquisition is expected to close in the third quarter, subject to shareholder and regulatory approvals.

Backstory: AtaiBeckley was created in 2025 through the combination of atai Life Sciences and Oxford-based Beckley Psytech.

• Atai was founded in 2018 and initially operated from Berlin, although it later adopted a transatlantic structure and listed on Nasdaq.
• Beckley Psytech was founded in Oxford in 2019 and grew out of decades of psychedelic research and advocacy led by British campaigner Amanda Feilding. Its lead drug, BPL-003, later became the central clinical asset behind the combined company and the main prize in Lilly’s acquisition.
• German entrepreneur Christian Angermayer is AtaiBeckley’s founder, chairman and largest shareholder, as well as the founder of investment firm Apeiron. Angermayer built his public profile through a wide-ranging portfolio spanning biotech, longevity, cryptocurrencies and other technology ventures. Psychedelic medicines became one of his signature investment themes and he also helped to found Compass Pathways, another UK-based psychedelic developer.

Zoom in: Lilly’s main target is BPL-003, an intranasal formulation of mebufotenin benzoate, a synthetic form of the psychedelic compound 5-MeO-DMT.

• The candidate is being developed for treatment-resistant depression. In a Phase 2b study, a single dose produced statistically significant reductions in depressive symptoms, with most patients considered ready to leave the clinic after around 90 minutes.
• The relatively short treatment window could be commercially important. Psychedelic therapies generally require patients to remain under medical supervision, creating a practical and financial barrier to their adoption.
• BPL-003 has received FDA Breakthrough Therapy designation and has entered Phase 3. Lilly will also acquire VLS-01, a DMT formulation delivered through a film placed inside the cheek that is currently in Phase 2b development.

By the numbers: Shareholders will receive $6.75 per share at closing, a 40% premium over the biotech’s 30-day volume-weighted average trading price. They can also receive contingent rights worth up to $2.50 per share that depend on milestones including the start of a Phase 3 trial for VLS-01 and US approvals and rescheduling decisions for BPL-003 and VLS-01.

The bigger picture: Europe provided much of the science, company formation and early capital behind AtaiBeckley, but the most advanced programmes are being developed primarily around the US regulatory and healthcare market. That reflects the uneven environment for psychedelic medicines. European research centres in the UK, Germany and Switzerland remain active, but the continent has yet to produce a clear regulatory route or a major approved therapy in the field.

Yes, but: The deal does not mean psychedelic medicines have overcome their clinical and regulatory risks. BPL-003 remains investigational, and its efficacy, safety and practical advantages must still be confirmed in Phase 3 trials. The FDA’s 2024 rejection of Lykos Therapeutics’ MDMA-assisted therapy also showed that positive enthusiasm around psychedelics does not guarantee approval.